Neurocrine reports Q1 adjusted EPS $1.94, consensus $1.70

Reports Q1 revenue $811M, consensus $767.88M. “Neurocrine’s (NBIX) strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and diversify across therapeutic areas,” said Kyle Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “We delivered $811 million in net product sales, representing 44% year-over-year growth, driven by continued strong demand for INGREZZA and CRENESSITY. Our recently announced agreement to acquire Soleno Therapeutics further underscores our commitment to address conditions with significant unmet need and accelerate revenue growth. With multiple first-in-class commercial medicines and the deepest pipeline in our history, Neurocrine is well-positioned to deliver transformative therapies for patients and drive sustained growth.”